Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;29(2):889-896.
doi: 10.1007/s00520-020-05561-3. Epub 2020 Jun 11.

Salivary biomarkers in breast cancer: a cross-sectional study

Pía López-Jornet  1   2 , Cristina Aznar  3 , Jose Ceron  4 , Tvarijonaviciute Asta  4
Affiliations

Salivary biomarkers in breast cancer: a cross-sectional study

Pía López-Jornet et al. Support Care Cancer. 2021 Feb.

Erratum in

Abstract

Aim: The objective was to evaluate the diagnostic value of salivary biomarkers in breast cancer.

Materials and methods: A prospective study was carried out of 91 consecutive breast cancer patients and 60 controls without neoplastic disease. Demographic data were recorded, along with the Hospital Anxiety Depression (HAD), risk for development periodontal diseases questionnaire and Mini-Nutritional Assessment (MNA) scores, and the TNM classification and stage of the primary tumor. Unstimulated basal saliva samples were collected and stored at - 80 °C until analysis.

Results: The mean salivary CA125 concentration was 102.1 pg/ml in the control group and 267.6 pg/ml in the breast cancer group (p = 0.005). The soluble Fas (sFas) concentration in turn was 84.1 pg/ml and 145.9 pg/ml, respectively (p = 0.008). None of the biomarkers was related to questionnaire-assessed risk for development of periodontal diseases. The area under the ROC curve was 0.68 for CA125 (95% CI, 0.05-0.56) and 0.67 for sFas (95% CI, 0.08-0.55).

Conclusions: The salivary biomarkers CA125 and sFas appear to be promising tools in the diagnosis of breast cancer.

Keywords: Breast cancer; CA125; Periodontal diseases; SFas; Salivary biomarkers.

PubMed Disclaimer

References

    1. DeSantis CE, Bray F, Ferlay J et al (2015) International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomark Prev 24:1495–1506. https://doi.org/10.1158/1055-9965.EPI-15-0535 - DOI
    1. Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM, Harvie MN (2014) Risk determination and prevention of breast cancer. Breast Cancer Res 16:446. https://doi.org/10.1186/s13058-014-0446-2 - DOI - PubMed - PMC
    1. McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 321:624–628. https://doi.org/10.1136/bmj.321.7261.624 - DOI - PubMed - PMC
    1. Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC (2014) Past, present, and future challenges in breast cancer treatment. J Clin Oncol 32:1979–1986. https://doi.org/10.1200/JCO.2014.55.4139 - DOI - PubMed - PMC
    1. Kaczor-Urbanowicz KE, Martín Carreras-Presas C, Kaczor T, Tu M, Wei F, Garcia-Godoy F, Wong DTW (2017) Emerging technologies for salivaomics in cancer detection. J Cell Mol Med 21:640–647. https://doi.org/10.1111/jcmm.13007 - DOI - PubMed

LinkOut - more resources